Edwards Lifesciences rises 9.127% after Q2 adjusted EPS and revenue beat estimates

Edwards Lifesciences’ second-quarter results crossed at 4:15:44 p.m. ET on July 23, with adjusted EPS of $0.78 versus $0.74 expected and revenue of $1.74 billion versus $1.70 billion expected. EW rose 1.818% in the first minute and was up 9.127% in the measured 10-minute post-market window. Against the $82.50 pre-headline baseline, the shares reached $90.03; the release-time snapshot was $82.00.

Growth extended across all three product groups

The company’s SEC-filed earnings release showed broad growth across its structural-heart portfolio. Total sales increased 13.6% year over year, or 12.5% at constant currency. Transcatheter aortic valve replacement sales reached $1.26 billion, up 11.3%, while transcatheter mitral and tricuspid therapies sales increased 47.3% to $195.9 million. Surgical sales rose 6.5% to $284 million.

Profitability also improved on an adjusted basis. Adjusted operating margin was 30.0%, up from 28.2% a year earlier, and adjusted EPS increased to $0.78 from $0.67. GAAP diluted EPS was $0.42. The reconciliation included a $188.2 million valuation allowance tied to a California tax-law change, alongside impairment and other specified adjustments.

Results exceeded Edwards’ prior quarterly range

The quarter also surpassed the company’s own earnings framework. In its April 23 first-quarter release, Edwards projected second-quarter sales of $1.66 billion to $1.74 billion and adjusted EPS of $0.70 to $0.76. Reported sales landed at the top of that range, while adjusted EPS came in above it.

Sales outlook moves higher

Management tightened several full-year growth ranges upward while keeping the profit target unchanged. Edwards raised total-company constant-currency sales growth guidance to 10% to 11% from 9% to 11%, TAVR growth to 8% to 9% from 7% to 9%, and TMTT sales guidance to $760 million to $780 million from $740 million to $780 million. It reaffirmed full-year adjusted EPS guidance of $2.95 to $3.05.

Third-quarter guidance calls for sales of $1.63 billion to $1.71 billion and adjusted EPS of $0.71 to $0.77. For active traders, the report paired a consensus beat with higher sales expectations and growth across TAVR, TMTT and Surgical rather than strength concentrated in one product line. The reaction assessment is limited to the stated post-market window and does not characterize later trading.